Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IntegenX today said that it has acquired a portfolio of DNA consumables products from GE Healthcare Bio-Sciences' subsidiary SV Corp.

The acquisition provides Pleasanton, Calif.-based IntegenX with an IP estate covering capillary electrophoresis, separation, sample preparation, and separation matrix technologies, according to IntegenX CEO Stevan Jovanovich.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.